Seeking Alpha

AstraZeneca's EPS misses consensus, revenue tops forecasts

  • AstraZeneca (AZN) core EPS of $1.17 misses by $0.06.
  • Revenues flat at $6.42B, topping consensus of $6.32B. Sales +3% at constant exchange rates (CER).
  • Core operating profit tumbles 11% to $1.95B.
  • Net profit halves to $504M from $1.01B, with earnings hurt by charges of $967M related to restructuring, amortization and other factors.
  • Sales breakdown: Brilinta $99M (+94% CER), diabetes $347M (+106%), respiratory $1.27B (+12%), emerging markets $1.42B (+11%) and Japan $537M (+13%).
  • AstraZeneca affirms its 2014 guidance, saying it expects core EPS to fall "in the teens" at CER and revenue to drop in the low-to-mid single digits on a percentage basis. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: